Rapoport, Bernardo LeonTheron, Annette J.Vorobiof, Daniel A.Langenhoven, LizanneHall, Jacqueline M.Van Eeden, Ronwyn I.Smit, TeresaChan, Sze-WaiBotha, Michael C.Raats, Johann I.De Necker, MargrietAnderson, Ronald2021-08-272021-08-272020-06Rapoport, B.L., Theron, A.J., Vorobiof, D.A., et al. 2020, ' Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer', Lung Cancer Management, vol. 9, no. 3, art. LMT37, pp. 1-12.1758-1966 (print)1758-1974 (online)10.2217/lmt-2020-0014http://hdl.handle.net/2263/81521AIM: We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab. MATERIALS & METHODS: This was a multicenter, noninterventional, retrospective data analysis, involving five oncology centers. RESULTS: Patients with prenivolumab NLR values of <5 and ≥5 had respective median overall survival (OS) values of 14.5 and 7.02 months (p = 0.0026). Patients with ≤2 and >2 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (p = 0.0174). A Cox multiple regression model revealed baseline NLR ≥5 as the only variable significantly associated with decreased OS (p < 0.0447). CONCLUSION: Pretreatment elevated NLR values are associated with poor outcomes in patients with recurrent metastatic non-small-cell lung cancer treated with nivolumab.en© 2020. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”).NivolumabPD-1 inhibitorPretherapy measurementNeutrophil/lymphocyte ratio (NLR)Non-small cell lung cancer (NSCLC)Article